Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

520
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
520
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.2K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Revised Adaptive Immune Receptor Data in the Immune Epitope Database.

bioRxiv : the preprint server for biology·2026
Same author

How does survodutide work? Plain language review of a potential new medication for obesity and liver disease.

Therapeutic advances in gastroenterology·2026
Same author

Challenges and future directions of AIRR-seq-based diagnostics.

Immunoinformatics (Amsterdam, Netherlands)·2026
Same author

Incidence of hospital admissions for AIDS-defining illness and intensive care unit admissions for individuals with HIV in Texas from 2006 to 2024.

Proceedings (Baylor University. Medical Center)·2026
Same author

Cardiovascular Disease and Obesity Medications in Older Women by Obesity-Related Cancers Status: SEER-Medicare 2007-2015.

Obesity (Silver Spring, Md.)·2026
Same author

VO: The Vaccine Ontology.

Scientific data·2026
Same journal

Shifts in Incident Glucose Lowering Drug Initiation in Type 2 Diabetes From 2014 to 2024: A Population-Based Study.

Diabetes, obesity & metabolism·2026
Same journal

Impact of Autoimmune Hypothyroidism and Celiac Disease on Progression to Diabetes in Individuals Positive for GAD65 or IA-2 Autoantibodies.

Diabetes, obesity & metabolism·2026
Same journal

The Ageing Adipose Paradox: Implications for Metabolic Health.

Diabetes, obesity & metabolism·2026
Same journal

Real-World Associations of KidneyIntelX Risk Stratification With Guideline-Directed Therapy, Kidney Outcomes, and Metabolic Trajectories in Early Diabetic Kidney Disease.

Diabetes, obesity & metabolism·2026
Same journal

Real-World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan.

Diabetes, obesity & metabolism·2026
Same journal

Cardiorenal Outcomes of Empagliflozin Versus Dapagliflozin in Secondary Prevention Among Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Nationwide Cohort Study.

Diabetes, obesity & metabolism·2026
See all related articles

Related Experiment Video

Updated: Mar 20, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

GLP-1 RAs and Kidney Cancer Risk: Methodological Considerations in Active-Comparator Selection

David S Lopez1,2, Omer Abdelgadir1, Jesús Gibran Hernández-Pérez1,3

  • 1Peter O'donnell School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Diabetes, Obesity & Metabolism
|March 19, 2026
PubMed
Summary

No abstract available in PubMed .

Keywords:
GLP‐1 RAkidney cancermethods researcheobesity

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.0K

Related Experiment Videos

Last Updated: Mar 20, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.0K